Wall Street Is Betting on Eli Lilly's GLP-1 Portfolio -- It's Missing the $1 Trillion Opportunity

Wall Street Is Betting on Eli Lilly's GLP-1 Portfolio -- It's Missing the $1 Trillion Opportunity

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow process measured in years and billions of dollars, is increasingly becoming a data-driven competition. Companies that combine proprietary medical data with AI tools may gain an advantage similar to what technology companies achieved during the ... Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Miss…